WVE earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -5.42. Updated 2026-07-23.
Wave Life Sciences (WVE) Research Hub
Wave Life Sciences (WVE) trades on NASDAQ, SG in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.59 USD (-4.57%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.42, market cap 1.09B. This hub links to the full technical, earnings and options research available for WVE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, SG |
| Last close | 4.59 USD (-4.57%) |
| 52-week range | 4.56 USD – 6.48 USD |
| Trend regime | Range |
| 14-day RSI | 23.9 (Oversold) |
| Trailing P/E | -5.42 |
| Market cap | 1.09B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for WVE
Covered Call on WVE: how it works, illustrative setup around the real 4.59 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on WVE: how it works, illustrative setup around the real 4.59 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on WVE: how it works, illustrative setup around the real 4.59 USD price, max profit/loss, breakeven and when to use it. Educational.
WVE technical analysis: range, last 4.59 USD, RSI 23.9, 52w range 4.56 USD–6.48 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is WVE in?
Wave Life Sciences (WVE) is classified under Healthcare (Biotechnology), listed on NASDAQ, SG.
Is WVE in an uptrend or downtrend?
As of 2026-09-11, WVE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is WVE's trailing P/E ratio?
WVE's trailing P/E is -5.42, with a market cap of 1.09B. See the earnings research page for full valuation detail.
When does WVE next report earnings?
WVE is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.31 USD.